HCW Biologics (HCWB) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2024	May 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	HCW Biologics Inc.
Entity Central Index Key	0001828673
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-5024477
Entity Address, Address Line One	2929 N
Entity Address, Address Line Two	Commerce Parkway
Entity Address, City or Town	Miramar
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33025
City Area Code	954
Local Phone Number	842–2024
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Title of 12(b) Security	Common Stock
Trading Symbol	HCWB
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		37,823,394
Entity File Number	001-40591

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,084,076	$ 3,595,101
Secured note receivable	250,000	0
Accounts receivable, net	903,884	1,535,757
Prepaid expenses	783,423	1,042,413
Other current assets	187,267	230,916
Total current assets	6,208,650	6,404,187
Investments	1,599,751	1,599,751
Property, plant and equipment, net	22,590,779	20,453,184
Other assets	28,476	56,538
Total assets	30,427,656	28,513,660
Current liabilities:
Accounts payable	10,493,416	6,167,223
Accrued liabilities and other current liabilities	2,919,190	2,580,402
Total current liabilities	13,412,606	8,747,625
Debt, net	8,274,449	6,304,318
Total Liabilities	21,687,055	15,051,943
Commitments and contingencies (Note 8)
Stockholders' equity:
Common Stock Value	3,782	3,603
Additional paid-in capital	86,737,203	83,990,437
Accumulated deficit	(78,000,384)	(70,532,323)
Total stockholders' equity	8,740,601	13,461,717
Total liabilities and stockholders' equity	$ 30,427,656	$ 28,513,660

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Condensed Balance Sheets [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	37,823,394	36,025,104

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenues	$ 1,126,712	$ 41,883
Cost of revenues	(511,965)	(29,350)
Net revenues	614,747	12,533
Operating expenses:
Research and development	2,123,284	2,255,813
General and administrative	5,985,126	3,117,290
Total operating expenses	8,108,410	5,373,103
Loss from operations	(7,493,663)	(5,360,570)
Interest expense	0	(93,438)
Other (expense) income, net	25,602	383,322
Net loss	$ (7,468,061)	$ (5,070,686)
Net loss per share, basic	$ (0.2)	$ (0.14)
Net loss per share, diluted	$ (0.2)	$ (0.14)
Weighted average shares outstanding, basic	37,223,588	35,883,779
Weighted average shares outstanding, diluted	37,223,588	35,883,779

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance (in shares) at Dec. 31, 2022		35,876,440
Beginning balance , Value at Dec. 31, 2022	$ 37,428,506	$ 3,588	$ 82,962,964	$ (45,538,046)
Issuance of Common Stock upon exercise of stock options, Shares		10,195
Issuance of Common Stock upon exercise of stock options , Value	1,901	$ 1	1,900
Stock-based compensation , Value	259,206		259,206
Net Income (Loss)	(5,070,686)			(5,070,686)
Ending balance (in shares) at Mar. 31, 2023		35,886,635
Ending balance , Value at Mar. 31, 2023	32,618,927	$ 3,589	83,224,070	(50,608,732)
Beginning balance (in shares) at Dec. 31, 2023		36,025,104
Beginning balance , Value at Dec. 31, 2023	13,461,717	$ 3,603	83,990,437	(70,532,323)
Issuance of Common Stock upon exercise of stock options, Shares		12,572
Issuance of Common Stock upon exercise of stock options , Value	2,255	$ 1	2,254
Issuance of Common Stock upon equity subscription,Shares.		1,785,718
Issuance of Common Stock upon equity subscription	2,500,005	$ 178	2,499,827
Stock-based compensation , Value	244,685		244,685
Net Income (Loss)	(7,468,061)			(7,468,061)
Ending balance (in shares) at Mar. 31, 2024		37,823,394
Ending balance , Value at Mar. 31, 2024	$ 8,740,601	$ 3,782	$ 86,737,203	$ (78,000,384)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net Income (Loss)	$ (7,468,061)	$ (5,070,686)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	243,501	298,847
Stock-based compensation	244,685	259,206
Unrealized loss (gain) on investments, net	0	(112,500)
Changes in the carrying amount of right-of-use asset	(418)	209
Changes in operating assets and liabilities:
Accounts receivable	631,873	164,967
Prepaid expenses and other assets	302,640	182,294
Accounts payable and other liabilities	2,498,451	718,675
Operating lease liability	(56,541)	(79,225)
Net cash used in operating activities	(3,603,870)	(3,638,213)
Cash flows from investing activities:
Purchases of property and equipment	(129,709)	(300,385)
Net cash used in investing activities	(129,709)	(300,385)
Cash flows from financing activities:
Proceeds from issuance of common stock	2,502,260	1,901
Proceeds from issuance of debt, net	1,750,000	0
Debt repayment	(29,706)	0
Net cash provided by financing activities	4,222,554	1,901
Net (decrease) increase in cash and cash equivalents	488,975	(3,936,697)
Cash and cash equivalents at the beginning of the period	3,595,101	22,326,356
Cash and cash equivalents at the end of the period	4,084,076	18,389,659
Supplemental disclosure of cash flow information:
Cash paid for interest, net of amounts capitalized	0	93,438
Noncash operating, investing and financing activities:
Capital expenditures accrued, but not yet paid	$ 2,192,255	$ 0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (7,468,061)	$ (5,070,686)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization HCW Biologics Inc. (the “Company”) is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. The Company believes age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company is located in Miramar, Florida and was incorporated in the state of Delaware in April 2018. Liquidity and Going Concern In accordance with ASC 205-40, Presentation of Financial Statements – Going Concern (“Topic 205-40”), we are required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance date of the Company’s condensed interim financial statements. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. As of March 31, 2024, the Company had not generated any revenue from commercial product sales of its internally-developed immunotherapeutic products for the treatment of cancer and other age-related diseases. In the course of its development activities, the Company has sustained operating losses and expects to continue to incur operating losses for the foreseeable future. Since inception to March 31, 2024, the Com pany incurred cumulative net losses of $ 75.5 million. As of March 31, 2024, the Company had $ 4.1 million in cash and cash equivalents. Management expects to incur additional losses in the future to conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. As a result of these conditions, substantial doubt about the Company’s ability to continue as a going concern was raised. To date, the Company has funded operations primarily through the sale of stock, issuance of senior secured notes and revenues generated from the Company’s exclusive worldwide license with Wugen, Inc. (“Wugen”), pursuant to which Wugen licensed limited rights to develop, manufacture, and commercialize cell therapy treatments for cancer based on two of the Company’s internally-developed multi-cytokine fusion protein molecules, and its manufacturing and supply arrangement with Wugen. In the three months ended March 31, 2023 and 2024, the Company recognized revenues of $ 41,883 and $ 1.1 million, respectively, genera ted from the supply of clinical and research grade material to Wugen. As of March 31, 2024, we held $ 4.1 million of cash and cash equivalents, and there was substantial doubt about the Company’s ability to continue as a going concern. Under the guidance of Topic 205-40 for going concern assessment, we evaluated whether we mitigated substantial doubt over our ability to remain a going concern. We considered that the Company is expecting to continue to generate losses as its products are in clinical development and will not generate commercial sales. Subsequent to the end of the first quarter, the Company raised $ 1.6 million in additional financing, consisting of funds received from the issuance of senior secured notes (“Secured Notes”) to the Company’s Founder and Chief Executive Officer. After considering management’s plan for financing and funds raised since year end, management concluded that substantial doubt is not alleviated. Therefore, substantial doubt remains over whether the Company has the ability to continue as a going concern within 12 months from the date of issuance of the condensed interim financial statements. In the second quarter of 2024, management made some reductions in costs, but in order to continue the clinical development for the Company’s lead product candidates, the Company must maintain a core group of scientists. The Company continues to pursue a plan to obtain bridge financing through the issuance of up to $ 10.0 million in Secured Notes, $ 3.6 million of which have been issued through the date of issuance of the condensed interim financial statements. The Company anticipates that this bridge financing, if fully subscribed, will allow the Company to reach such time as it can execute plans for business development transactions such as licenses for non-core assets and capital-raising transactions, although there can be no assurance of this outcome for many reasons, including the uncertainties regarding the Company’s ongoing arbitration proceedings with Altor/NantCell, as described in Note 8. In addition to the bridge financing in the form of the sale of additional Secured Notes, other potential near-term financing plans may include cooperative agreements for clinical trials and third-party collaboration funding. If the Company is not successful in raising additional capital, management has the intent and ability to revise its business plan and reduce costs. If such revisions are insufficient, the Company may have to curtail or cease operations. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company’s condensed interim financial statements, without additional funding or financial support. After considering management’s plan for financing and funds raised that are probable to occur within one year, as well as that the Company expects to continue to incur losses from operations for the foreseeable future, management concluded that the substantial doubt that existed in its going concern analysis was not alleviated. Summary of Significant Accounting Policies Basis of Presentation Unaudited Interim Financial Information The accompanying unaudited condensed interim financial statements as of March 31, 2024 and for the three-month periods ended March 31, 2023 and 2024 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed interim financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three-month period ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The condensed interim balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed interim financial statements and the notes accompanying them should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023 which appear in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024 (the “Annual Report”) and in other filings with the SEC. Revenue Recognition The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“Topic 606”). To determine revenue recognition for arrangements that fall within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, the Company's revenues have been generated solely from transactions with Wugen. The Wugen License includes licenses of intellectual property, cost reimbursements, upfront signing fees, milestone payments and royalties on future licensee’s product sales. In addition, the Company and Wugen have an agreement for supply of materials, from which the Company also recognizes revenues. License Grants: For out-licensing arrangements that include a grant of a license to the Company’s intellectual property, the Company considers whether the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement. Milestone and Contingent Payments: At the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of each such milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments, the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result in recognizing revenue for previously satisfied performance obligations in such period. The Company’s licensees will generally pay milestones payments subsequent to achievement of the triggering event. Materials Supply: The Company provides clinical and research grade materials so that licensees may develop products based on the licensed molecules. The Company plans to enter into commercialization supply agreements when licensees enter the commercial stage of their company. The amounts billed are recognized as revenue as the performance obligations are satisfied by the Company, once the Company determines that a contract exists. On June 18, 2021, the Company entered into a master services agreement (“MSA”) for the supply of materials for clinical development of licensed products. On March 14, 2022, the Company entered into statements-of-work (“SOWs”) contemplated under the MSA for all current and historical purchases of clinical and research grade materials. The Company determined that upon entering into the SOWs all requirements were met to qualify as a contract under Topic 606. The manufacturing of the clinical and research materials supplied by the Company each represents a single performance obligation that is satisfied over time. The Company recognizes revenue using an input method based on the costs incurred relative to the total expected cost, which determines the extent of the Company's progress toward completion. As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgement to determine the progress towards completion. The Company reviews its estimate of the progress toward completion based on the best information available to recognize the cumulative progress toward completion as of the end of each reporting period, and makes revisions to such estimates, if facts and circumstances change during each reporting period. For the three months ended March 31, 2024, the Company recogni zed $ 1.1 million in re venue related to sale of development supply materials. Investments The Company holds a minority interest in Wugen which is accounted for using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment has been recognized. As of March 31, 2024 and December 31, 2023, the Compa ny included $ 1.6 million for the investment in Wugen in Investments in the accompanying condensed interim balance sheets. The Company used its equity interest in Wugen to collateralize the Secured Notes. See Note 3. Debt, Net. The Company invests excess cash in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2023 and March 31, 2024 , the Company had no Short-term investments. Operating Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in Other assets, Accrued liabilities and other current liabilities, and Other liabilities on its condensed interim balance sheets. Operating lease Right of Use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has a lease agreement with lease and non-lease components, which are accounted for separately. For short-term leases with a term of one year or less, the Company uses the practical expedient and does not record an ROU asset or lease liability for such short-term leases. Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise of stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

Accrued Liabilities and Other C

Accrued Liabilities and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Liabilities and Other Current Liabilities	2. Accrued Liabilities and Other Current Liabilities As of December 31, 2023 , the Company had a balance of $ 2.6 million included in Accrued liabilities and other current liabilities i n the audited balance sheet, consisting of $ 392,000 for construction expenses, $ 105,000 for manufacturing expenses, $ 1.1 million for legal fees, $ 262,000 for clinical expenses, $ 365,000 for bonus payable, $ 160,000 for salary expenses, $ 119,000 for the current portion of long-term debt, $ 28,500 for a lease liability and $ 68,500 for other liabilities. As of March 31, 2024 , the Company had a balance of $ 2.9 million included in Accrued liabilities and other current liabilities in the accompanying condensed interim balance sheet, consisting of $ 1.6 million for legal fees, $ 874,000 for construction in progress, $ 202,000 for clinical expenses, $ 57,000 for bonus payable, $ 122,152 for the current portion of long-term debt and $ 102,000 for salary and benefits.

Debt, Net

Debt, Net	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt, Net	3. Debt, Net Cogent Bank Loan On August 15, 2022, the Company entered into a loan and security agreement (the “2022 Loan Agreement”) with Cogent Bank, pursuant to which it received $ 6.5 million in proceeds to purchase a building that will become the Company's new headquarters. The loan is secured by a first priority lien on the building. As of March 31, 2024, the Company had $ 6.4 million in principal outstanding in a loan under the 2022 Loan Agreement. The interest-only period was one year followed by 48 months of equal payments of principal and interest beginning on September 15, 2023 based on a 25-year amortization rate. The unamortized balance is due on August 15, 2027 (the “Maturity Date”), and bears interest at a fixed per annum rate equal to 5.75 %. Upon the Maturity Date, a final payment of unamortized principal will be due. The Company is in compliance with all covenants as of March 31, 2024. The Company has the option to prepay the outstanding balance of the loan prior to the Maturity Date without penalty. As of March 31, 2024, the current portion of $ 122,152 is included in Accrued liabilities and other current liabilities, and the noncurrent portion of $ 6.4 million is included in Debt, net in the accompan y ing condensed interim balance sheet. Senior Secured Notes On March 28, 2024, the Company entered into the Note Purchase Agreement with the Purchasers (as defined in the Note Purchase Agreement), pursuant to which the Company may issue Secured Notes up to an aggregate principal amount up to $ 10.0 million, and issued $ 2.0 million of Secured Notes to certain accredited investors. Secured Notes were issued to the following investors: Dr. Hing C. Wong, Founder and Chief Executive Officer, who invested $ 620,000 ; Rebecca Byam, Chief Financial Officer, who invested $ 220,000 ; and Gary M. Winer, member of our Board of Directors, who invested $ 50,000 , as well as unrelated parties. As of March 31, 2024, the Company received $ 1.8 million in cash payments for the Secured Notes. A check payment of $ 250,000 , that has since cleared, is included in Secured note receivable in the accompanying condensed interim balance sheet. The Note Purchase Agreement sets forth the terms and conditions, including representations and warranties, for our issuance and sale of the Secured Notes to the Purchasers. The indebtedness for the Secured Notes is included in Debt, net in the accompanying condensed interim balance sheet. The Senior Notes bear interest at a rate of 9 % per annum, payable quarterly in arrears, and mature on March 27, 2026 (the “Maturity Date”), on which date the principal balance and accrued but unpaid interest under the Secured Notes shall be due and payable. If the Company elects to prepay the Senior Notes prior to the Maturity Date, there is a 5 % prepayment penalty. As security for the Secured Notes, the Company pledged its equity ownership interest in Wugen, which was equivalent to a 5.6 % ownership stake in that company as of March 31, 2024 (“Pledged Collateral”). The Pledged Collateral will be held and released according to the terms of the Escrow Agreement, as security for the Secured Notes. The Secured Notes have a Mandatory Prepayment provision, according to which the Company is required to prepay the Secured Notes under certain circumstances. The Note Purchase Agreement also contains default provisions, according to which the Company shall be required to distribute the Pledged Collateral to the Purchasers on a pro rata basis, in full satisfaction of the indebtedness evidenced by the Secured Notes.

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Preferred Stock	4. Preferred Stock As of December 31, 2023 and March 31, 2024 , the Company had 10,000,000 shares of preferred stock authorized and no shares issued.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	5. Net Loss Per Share The following table summarizes the computation of the basic and diluted net loss per share: Three Months Ended March 31, 2023 2024 Numerator: Net loss $ ( 5,070,686 ) $ ( 7,468,061 ) Denominator: Weighted-average common shares outstanding 35,883,779 37,223,588 Net loss per share, basic and diluted $ ( 0.14 ) $ ( 0.20 ) The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive: At March 31, 2023 2024 Common stock options 1,856,463 1,764,766 Potentially dilutive securities 1,856,463 1,764,766

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	6. Fair Value of Financial Instruments The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, U.S. government-backed securities with maturity dates up to one year, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities. Money market funds included in cash and cash equivalents and U.S. government-backed securities are measured at fair value based on quoted prices in active markets, which are considered Level 1 inputs. No transfers between levels occurred during the periods presented. The following table presents the Company’s assets which were measured at fair value at December 31, 2023 and March 31, 2024: At December 31, 2023: Level 1 Level 2 Level 3 Total Assets: Money market funds $ 1,626,129 $ — $ — $ 1,626,129 Total $ 1,626,129 $ — $ — $ 1,626,129 At March 31, 2024: Level 1 Level 2 Level 3 Total Assets: Money market funds $ 703,325 $ — $ — $ 703,325 Total $ 703,325 $ — $ — $ 703,325

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The Company computes its quarterly income tax expense/(benefit) by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The Company did no t have a provision for income taxes (current or deferred tax expense) as of December 31, 2023 and March 31, 2024. The Company will continue to maintain a 100 % valuation allowance on total deferred tax assets. The Company believes it is more likely than not that the related deferred tax assets will not be realized. As a result, the Company’s effective tax rate will remain at 0.00 % because no items either estimated or discrete items would impact the tax provision.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases The Company has operating leases for approximately 12,250 square feet of space located in Miramar, Florida. The leases have a two-year term which commenced on March 1, 2022 and terminated on February 29, 2024 . Upon the commencement of the leases, the Company used its incremental borrowing rate of 6.0 % to determine the amounts to recognize for a ROU asset and a lease liability. The Company entered a new one-year lease for the same location which commenced on March 1, 2024 and terminates on February 28, 2025. If a lease has a term that is 12 months or less in duration, the lease qualifies for a short-term lease exemption under ASC 842-20-25-2. The Company elected to take advantage of this exemption, and it will account for this lease on a straight-line basis over the lease term and will not recognize a ROU asset and a lease liability as a resul t. The remaining lease payments under the new short-term lease are $ 251,921 . The Company has no obligations under finance leases. The components of the lease expense for the three months ended March 31, 2024 were as follows: For the Three Months Operating lease cost $ 28,275 Supplemental cash flow information related to the Company’s operating lease was as follows: For the Three Months Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows $ 28,793 Right-of-use assets obtained in exchange for lease obligations: Operating lease $ 28,061 For the three months ended March 31, 2023 and 2024 , rent expense recognized by the Company was $ 43,950 and $ 47,838 , respectively, of which $ 22,212 and $ 23,453 , respectively, are included in research and development in the accompanying condensed interim statements of operations . Contractual Commitments The Company has commitments with a third-party manufacturing organization to supply us with clinical grade materials. As of March 31, 2024 , it is under contract for obligations of $ 649,517 it expects to pay during the year ending December 31, 2024. As of December 31, 2023 and March 31, 2024, the Company had commitments to fund $ 4.4 million and $ 2.8 million, respectively, in construction costs related to the buildout of its new headquarters and manufacturing facility. Project Financing On January 10, 2024 (the “Termination Date”), the Company exercised its right to terminate its credit agreement (the “Credit Agreement”), dated April 21, 2023, with Prime Capital Ventures, LLC (the “Lender”), as permitted under the terms of the Credit Agreement. The termination followed repeated delays in funding and related concerns. There were no borrowings under the Credit Agreement as of the Termination Date, and the Company did not incur any penalties as a result of such termination under the terms of the Agreement. Upon exercising its right to terminate the Agreement, the Company was entitled to receive the return of the $ 5.3 million that the Company placed on deposit to establish an interest reserve account with the Lender. In the three months ended March 31, 2024, the Lender defaulted on its obligation to return the interest reserve deposit. Given the uncertainty of when or if funds will be recovered from the Lender, the Company recognized a reserve for a credit loss for $ 5.3 million as of December 31, 2023. The Company intends to pursue all available remedies to recover these funds, including legal actions, receivership and insurance. Legal Legal Proceedings From time to time, the Company is a party to or otherwise involved in legal proceedings, including suits, assessments, regulatory actions and investigations generally arising out of the normal course of business. In addition, the Company enters into agreements that may include indemnification provisions, pursuant to which the Company agrees to indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. When the Company believes that the outcome of such a matter will result in a liability that is probable to be incurred and result in a potential loss, or range of loss, that can be reasonably estimated, the Company will accrue a liability and make the appropriate disclosure in the footnotes to the financial statements. On December 23, 2022, Altor BioScience, LLC and NantCell, Inc. (“Altor/NantCell”) initiated an arbitration against Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, in California alleging breach of contract and fiduciary duty, among other claims. On that same date, Altor/NantCell filed a lawsuit against the Company in federal court alleging misappropriation of trade secrets, inducement of breach of contract and breach of fiduciary duty, among other claims against the Company. On January 31, 2023, the Company filed a motion to compel arbitration, a motion for the stay of the litigation, and a motion to dismiss the complaint (“motion to compel”). On April 18, 2023, the U.S. District Court for the Southern District of Florida (the “Court”) heard oral argument on the Company’s motion to compel and ordered the parties to provide supplemental briefing by April 28, 2023. Before the Court ruled on the Company’s motion to compel, on April 26, 2023, the parties stipulated that Altor/NantCell’s action against the Company would be consolidated with the Altor/NantCell arbitration demand against Dr. Wong. On April 27, 2023, the Court approved the parties’ stipulation and ordered the parties to arbitration. On May 1, 2023, Altor/NantCell filed a demand against the Company before JAMS. On May 3, 2023, Altor/NantCell dismissed the federal court action without prejudice and the Court ordered the case dismissed without prejudice and closed the case. Altor/NantCell’s proceeding against the Company is now proceeding in arbitration before JAMS and is consolidated with the arbitration Altor/NantCell initiated against Dr. Wong. The arbitration hearing is scheduled to begin on May 20, 2024. In addition, on March 26, 2024, Altor/NantCell filed a complaint (the “Complaint”) against the Company in the Chancery Court of the State of Delaware for the contribution of legal fees and expenses advanced to Dr. Wong, our founder and chief executive officer, in connection with the arbitration discussed above. Prior to the filing of the Complaint, Altor/NantCell had previously sought advancement from the Company and the Company agreed to advance 50 % of Dr. Wong’s legal fees going forward from December 2023. On January 8, 2024, Altor/NantCell reserved their right to pursue contribution against the Company for 50 % of the amount Altor/NantCell sent for advancement of expenses for Dr. Wong. In the Complaint, Altor/NantCell seek 50 % of the fees they have already advanced to Dr. Wong, a declaration that the Company has an obligation to contribute 50 % of the advancement of Dr. Wong’s expenses including 50 % of Dr. Wong’s expenses incurred in connection with the arbitration through final resolution of the matter, and costs and fees in bringing this action. Other Matters Prior to the date of issuance, certain subcontractors filed mechanics liens related to unpaid invoices issued in connection with the Company’s construction of its new manufacturing facilities and upgraded research laboratories. The Company continues to seek a lender to provide financing to complete this project. Inflationary Cost Environment, Banking Crisis, Supply Chain Disruption and the Macroeconomic Environment The Company’s operations have been affected by many headwinds, including inflationary pressures, rising interest rates, ongoing global supply chain disruptions resulting from increased geopolitical tensions such as the war in the Middle East, the conflict between Russia and Ukraine, China-Taiwan relations, financial market volatility and currency movements. The Company has been impacted by inflation, and may continue to be so, when procuring materials required for the buildout of our new headquarters, the costs for recruiting and retaining employees and other employee-related costs. Management employs a number of strategies to effectively navigate these issues, including product redesign, alternate sourcing, and establishing contingencies in budgeting and timelines. Future developments in these and other areas present material uncertainty and risk with respect to the Company's clinical trials, IND-enabling activities, buildout of the new headquarters, as well as the Company's financial condition and results of operations. The extent and duration of such events and conditions, and resulting disruptions to our operations, are highly unpredictable.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events Subsequent events have been evaluated through the date the financial statements were filed. In addition to the required recognition or disclosure disclosed in the footnotes herein, there were also the following subsequent events after the reporting date: On May 13, 2024, the Company’s Founder and Chief Executive Officer purchased an additional $ 1.6 million in Secured Notes, bringing his total purchases of Secured Not es to $ 2.2 million. The Board of Directors and the Audit Committee of the Board of Directors reviewed the transaction under the Company’s policy for Related Party Transactions (the “Policy”) and determined that the transaction was in compliance with the Policy.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Unaudited Interim Financial Information The accompanying unaudited condensed interim financial statements as of March 31, 2024 and for the three-month periods ended March 31, 2023 and 2024 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed interim financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three-month period ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The condensed interim balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed interim financial statements and the notes accompanying them should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023 which appear in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024 (the “Annual Report”) and in other filings with the SEC.
Revenue Recognition	Revenue Recognition The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“Topic 606”). To determine revenue recognition for arrangements that fall within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, the Company's revenues have been generated solely from transactions with Wugen. The Wugen License includes licenses of intellectual property, cost reimbursements, upfront signing fees, milestone payments and royalties on future licensee’s product sales. In addition, the Company and Wugen have an agreement for supply of materials, from which the Company also recognizes revenues. License Grants: For out-licensing arrangements that include a grant of a license to the Company’s intellectual property, the Company considers whether the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement. Milestone and Contingent Payments: At the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of each such milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments, the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result in recognizing revenue for previously satisfied performance obligations in such period. The Company’s licensees will generally pay milestones payments subsequent to achievement of the triggering event. Materials Supply: The Company provides clinical and research grade materials so that licensees may develop products based on the licensed molecules. The Company plans to enter into commercialization supply agreements when licensees enter the commercial stage of their company. The amounts billed are recognized as revenue as the performance obligations are satisfied by the Company, once the Company determines that a contract exists. On June 18, 2021, the Company entered into a master services agreement (“MSA”) for the supply of materials for clinical development of licensed products. On March 14, 2022, the Company entered into statements-of-work (“SOWs”) contemplated under the MSA for all current and historical purchases of clinical and research grade materials. The Company determined that upon entering into the SOWs all requirements were met to qualify as a contract under Topic 606. The manufacturing of the clinical and research materials supplied by the Company each represents a single performance obligation that is satisfied over time. The Company recognizes revenue using an input method based on the costs incurred relative to the total expected cost, which determines the extent of the Company's progress toward completion. As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgement to determine the progress towards completion. The Company reviews its estimate of the progress toward completion based on the best information available to recognize the cumulative progress toward completion as of the end of each reporting period, and makes revisions to such estimates, if facts and circumstances change during each reporting period. For the three months ended March 31, 2024, the Company recogni zed $ 1.1 million in re venue related to sale of development supply materials.
Investments	Investments The Company holds a minority interest in Wugen which is accounted for using the measurement alternative whereby the investment is recorded at cost less impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same investee. No impairment has been recognized. As of March 31, 2024 and December 31, 2023, the Compa ny included $ 1.6 million for the investment in Wugen in Investments in the accompanying condensed interim balance sheets. The Company used its equity interest in Wugen to collateralize the Secured Notes. See Note 3. Debt, Net. The Company invests excess cash in bills and notes issued by the U.S. Treasury which are classified as trading securities. As of December 31, 2023 and March 31, 2024 , the Company had no Short-term investments.
Operating Leases	Operating Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in Other assets, Accrued liabilities and other current liabilities, and Other liabilities on its condensed interim balance sheets. Operating lease Right of Use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has a lease agreement with lease and non-lease components, which are accounted for separately. For short-term leases with a term of one year or less, the Company uses the practical expedient and does not record an ROU asset or lease liability for such short-term leases.
Net Loss Per Share	Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise of stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Income (Loss) Per Common Share	The following table summarizes the computation of the basic and diluted net loss per share: Three Months Ended March 31, 2023 2024 Numerator: Net loss $ ( 5,070,686 ) $ ( 7,468,061 ) Denominator: Weighted-average common shares outstanding 35,883,779 37,223,588 Net loss per share, basic and diluted $ ( 0.14 ) $ ( 0.20 )
Summary of Outstanding Potentially Dilutive Securities	The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive: At March 31, 2023 2024 Common stock options 1,856,463 1,764,766 Potentially dilutive securities 1,856,463 1,764,766

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of assets and liabilities that are measured at fair value on a recurring basis	The following table presents the Company’s assets which were measured at fair value at December 31, 2023 and March 31, 2024: At December 31, 2023: Level 1 Level 2 Level 3 Total Assets: Money market funds $ 1,626,129 $ — $ — $ 1,626,129 Total $ 1,626,129 $ — $ — $ 1,626,129 At March 31, 2024: Level 1 Level 2 Level 3 Total Assets: Money market funds $ 703,325 $ — $ — $ 703,325 Total $ 703,325 $ — $ — $ 703,325

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Summary of components of the lease expense	The components of the lease expense for the three months ended March 31, 2024 were as follows: For the Three Months Operating lease cost $ 28,275
Summary of supplemental cash flow information related to the company operating lease	Supplemental cash flow information related to the Company’s operating lease was as follows: For the Three Months Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows $ 28,793 Right-of-use assets obtained in exchange for lease obligations: Operating lease $ 28,061

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	May 13, 2024	Mar. 28, 2024	Dec. 31, 2023
Revenue recognized	$ 1,126,712	$ 41,883
Financing amount			$ 1,600,000
Investment impairment charges	0
Common Stock Value	$ 3,782				$ 3,603
Common Stock, Shares, Issued	37,823,394				36,025,104
Short-term investments	$ 0				$ 0
Cash and cash equivalents	4,084,076				3,595,101
Research and development	75,500,000
Senior Secured Notes
Debt Instrument, Face Amount				$ 1,800,000
Senior Secured Notes | Subsequent Event
Debt Instrument, Face Amount			3,600,000
Senior Secured Notes | Founder and CEO | Subsequent Event
Debt Instrument, Face Amount			$ 1,600,000
Maximum | Senior Secured Notes
Debt Instrument, Face Amount	10,000,000			$ 10,000,000
Wugen License
Revenue recognized	1,100,000	$ 41,883
Investments	$ 1,600,000				$ 1,600,000

Accrued Liabilities and Other_2

Accrued Liabilities and Other Current Liabilities - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Payables And Accruals [Line Items]
Accrued liabilities and other current liabilities	$ 2,919,190	$ 2,580,402
Accounts Payable and Accrued Liabilities, Current	2,900,000	2,600,000
Accrued Expenses Current [Member]
Payables And Accruals [Line Items]
short term lease liability		28,500
Accounts Payable and Accrued Liabilities [Member]
Payables And Accruals [Line Items]
Salaries and Employee Benefits	102,000
Construction expenses		392,000
Manufacturing expenses		105,000
Construction in progress	874,000
Legal Fees	1,600,000	1,100,000
Clinical expenses	202,000	262,000
Bonus payable	57,000	365,000
Salary expense		160,000
Current portion of long term debt	$ 122,152	119,000
Other liabilities		$ 68,500

Debt, Net - Additional Informat

Debt, Net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 28, 2024	Dec. 31, 2023	Aug. 15, 2022
Line of Credit Facility [Line Items]
Debt	$ 8,274,449		$ 6,304,318
Wugen License
Line of Credit Facility [Line Items]
Pledged collateral percentage	5.60%
Chief Executive Officer
Line of Credit Facility [Line Items]
Accredited investors principal amount		$ 620,000
Chief Financial Officer
Line of Credit Facility [Line Items]
Accredited investors principal amount		220,000
Board Of Directors
Line of Credit Facility [Line Items]
Accredited investors principal amount		50,000
Senior Secured Notes
Line of Credit Facility [Line Items]
Maturity date	Mar. 27, 2026
Principal amount		1,800,000
Interest rate	9%
Penalty percentage	5%
Senior Secured Notes | Maximum
Line of Credit Facility [Line Items]
Principal amount	$ 10,000,000	$ 10,000,000
Cogent Bank Member
Line of Credit Facility [Line Items]
Proceeds to purchase				$ 6,500,000
Principal outstanding	$ 6,400,000
Line Of credit facility frequency of payments	The interest-only period was one year followed by 48 months of equal payments of principal and interest
Maturity date	Aug. 15, 2027
Credit facility interest rate during period	5.75%
Debt, current portion	$ 122,152
Debt	$ 6,400,000

Debt, Net - Schedule of Maturit

Debt, Net - Schedule of Maturities of Long-term Debt (Details) $ in Millions	Mar. 28, 2024 USD ($)
Debt Disclosure [Abstract]
Total Debt	$ 2

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - shares	Mar. 31, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net Income (Loss)	$ (7,468,061)	$ (5,070,686)
Denominator:
Weighted average shares outstanding, basic	37,223,588	35,883,779
Weighted average shares outstanding, diluted	37,223,588	35,883,779
Net loss per share, basic	$ (0.2)	$ (0.14)
Net loss per share, diluted	$ (0.2)	$ (0.14)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,764,766	1,856,463
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,764,766	1,856,463

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets:
Assets	$ 703,325	$ 1,626,129
Money Market Funds [Member]
Assets:
Assets	703,325	1,626,129
Level 1 [Member]
Assets:
Assets	703,325	1,626,129
Level 1 [Member] | Money Market Funds [Member]
Assets:
Assets	703,325	1,626,129
Level 2 [Member]
Assets:
Assets	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets:
Assets	0	0
Level 3 [Member]
Assets:
Assets	0	0
Level 3 [Member] | Money Market Funds [Member]
Assets:
Assets	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0
Deferred Tax Assets Valuation Allowance, Percent	100%
Effective Income Tax Rate Reconciliation, Percent	0%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($) ft²	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Jan. 10, 2024 USD ($)	Jan. 08, 2024	Mar. 01, 2022
Operating Leased Assets [Line Items]
Area of land | ft²	12,250
Lease term							2 years
Lease termination date	Feb. 29, 2024
Operating Lease, Weighted Average Discount Rate, Percent	6%
Short-term lease	$ 251,921
Operating Leases, Rent Expense	47,838	$ 43,950
Operating lease	28,061
Commitment fund	$ 2,800,000		$ 4,400,000
Deposit for interest reserve					$ 5,300,000
Deposit for credit loss reserve			$ 5,300,000
Perecentage of legal fees	50%
Percentage of advancement of expenses						50%
Percentage of legal fees already advanced						50%
Percentage of contribution of advancement of expenses						50%
Percentage of expenses related to arbitration						50%
Forecast Member
Operating Leased Assets [Line Items]
Future payment obligations				$ 649,517,000,000
Research and Development Expense [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$ 23,453	$ 22,212

Commitments and Contingencies_2

Commitments and Contingencies - Summary of components of the lease expense (Detail)	3 Months Ended
	Mar. 31, 2024 USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating lease cost	$ 28,275

Commitments and Contingencies_3

Commitments and Contingencies - Summary of supplemental cash flow information related to the company operating lease (Detail)	3 Months Ended
	Mar. 31, 2024 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows	$ 28,793
Right-of-use assets obtained in exchange for lease obligations:
Operating lease	$ 28,061

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Senior Secured Notes - USD ($) $ in Millions	May 13, 2024	Mar. 28, 2024
Subsequent Event [Line Items]
Debt Instrument, Face Amount		$ 1.8
Subsequent Event
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 3.6
Total purchases of secured notes	2.2
Subsequent Event | Founder and CEO
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 1.6